Harpoon Therapeutics to Report Fourth Quarter and Full Year 2018 Financial Results

Webcast and Conference Call to be Held at 4:30 p.m. ET on March 14, 2019

SOUTH SAN FRANCISCO, Calif., March 07, 2019 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, announced today that it will report fourth quarter and full year 2018 financial results and provide a corporate update on Thursday, March 14, 2019. Harpoon’s management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT.

The live call may be accessed by dialing 866-951-6894 for domestic callers and 409-216-0624 for international callers and entering the conference code: 2497976. A live webcast and archive of the call will be available online from the investor relations section of the company website at www.harpoontx.com.

About Harpoon Therapeutics

Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct™ (TriTAC) platform, Harpoon is developing a pipeline of novel T cell engagers, or TriTACs, initially focused on the treatment of solid tumors and hematologic malignancies. For additional information about Harpoon Therapeutics, please visit www.harpoontx.com.


Harpoon Therapeutics, Inc.
Georgia Erbez
Chief Financial Officer

Westwicke Partners, LLC.
Robert H. Uhl
Managing Director